SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Preventive Visit — Jacqueline du Pré — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJacqueline Mary du Pré
Date of birth1945-01-26
IdentifiersMRN HR-ML039-SYN-TD; SSN (made up) 000-39-7062
Document date1973-09-14
AuthorImogen Thackeray-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic adult preventive visit. [S]

History of Present Illness

Ms. du Pré, 28, comes for her yearly preventive visit five months after starting ocrelizumab. She has had no relapse; the cystitis in June cleared with nitrofurantoin and the tingling that came with it went within two days. She practices three to four hours a day, played chamber music in public last month for the first time this year, and teaches two students a week. Fatigue comes in the late afternoon and she plans her day around it. She takes cholecalciferol 4000 units daily. Her PHQ-9 today is 3. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 28
Active conditionsRelapsing-remitting multiple sclerosis on ocrelizumab; vitamin D deficiency on replacement
MedicinesOcrelizumab every six months (next dose next month); cholecalciferol 4000 units daily
MoodPHQ-9 3

Health risk assessment. Completed by the patient on a tablet in the waiting room and reviewed with her by Dr. Thackeray-Osei. [S]

DomainFinding
Self-rated healthGood, and much better than in the spring
PsychosocialBusy with practice, teaching and concerts; worries about another relapse; good support from friends
TobaccoNever smoked
Alcohol and drugsA glass of wine two or three evenings a week; no drugs
Physical activitySwims twice a week and walks daily, as the occupational therapist suggested for fatigue
NutritionRegular meals; no restrictions
SleepEight hours; rests for half an hour after lunch
Sexual and reproductive healthCondoms used consistently; not planning a pregnancy this year
Safety at homeFeels safe; no one hurts, threatens or controls her
Road safetyWears a seat belt; does not drive when tired
Activities of daily livingIndependent

Review of Systems

SystemResultFinding
ConstitutionalPositiveLate-afternoon fatigue, managed with pacing; no fever or weight loss
EyesNegativeNo blurred vision or pain on moving the eyes
Ears, nose, mouth, and throatNegativeNo hearing change
CardiovascularNegativeNo chest pain or palpitations
RespiratoryNegativeNo cough or breathlessness
GastrointestinalNegativeBowels regular
GenitourinaryNegativeNo urgency or burning since June
BreastNegativeNo lump
MusculoskeletalNegativeSome neck and shoulder stiffness after long practice
IntegumentaryNegativeNo rash or changing moles
NeurologicalPositiveFaint tingling in the left fingertips after long practice; no weakness or imbalance
PsychiatricNegativeMood good; PHQ-9 3; no thoughts of self-harm

12 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Nitrofurantoin macrocrystals 100 mg oral capsule, one capsule by mouth twice daily with food for 5 daysOne capsule twice daily for 5 daysOral route1973-06-15 to 1973-06-19completedS
Methylprednisolone 1000 mg injection, 1 g intravenously over one hour once daily for 3 days1 g daily for 3 daysIntravenous route1973-03-24 to 1973-03-26completedS
Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth dailyOne capsule dailyOral route1973-03-23activeS
Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion300 mg on days 1 and 15, then 600 mg every 6 monthsIntravenous route1973-04-13activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1973-09-14Body height173cmS
1973-09-14Body weight63.9kgS
1973-09-14Body mass index (BMI) [Ratio]21.4kg/m2S
1973-09-14Systolic blood pressure110mm[Hg]S
1973-09-14Diastolic blood pressure70mm[Hg]S
1973-09-14Heart rate68/minS
1973-09-14Respiratory rate14/minS
1973-09-14Body temperature36.6CelS
1973-09-14Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1973-09-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 1973-09-14; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWell; weight 63.9 kg, BMI 21.4; blood pressure 110/70
Head, eyes, ears, nose, and throatNormal; fundi normal
NeckNo lymph nodes; thyroid normal
BreastsExamined with her agreement and a chaperone: no mass or nipple discharge; no axillary nodes
CardiovascularRegular rhythm; no murmur
RespiratoryClear to auscultation bilaterally
AbdomenSoft, non-tender
SkinNo rash; no suspicious moles
MusculoskeletalTight upper trapezius muscles; full neck movement
NeurologicalVibration slightly reduced in the left fingertips only; strength, reflexes and gait normal
PsychiatricBright, warm and engaged

Problems

ProblemClinical statusVerificationCodeProvenance
Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this weekresolvedconfirmed R20.2S — Synthetic presenting problem anchored to her documented loss of sensation in her fingers and fatigue. Superseded by the diagnosis at the second visit.
Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 1964 McDonald criteria and the 1971 revision; synthetic modern detail linked to her documented diagnosisactiveconfirmed G35.AS — Synthetic course, imaging and laboratory detail; linked to her documented diagnosis in October 1973.
Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosisactiveconfirmed E55.9S — Synthetic finding.
Acute uncomplicated cystitis (Escherichia coli) seven weeks after the first ocrelizumab course, with a pseudo-relapse: two days of returning tingling in the fingers with a low fever and no new neurological deficit; resolvedresolvedconfirmed N30.00S — Synthetic intercurrent infection; not a historical claim.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Blood pressure screeningCompleted today110/70 mmHg
Depression screeningCompleted todayPHQ-9 score 3; item 9 scored 0
Unhealthy alcohol use screeningCompleted todayTwo or three glasses of wine a week; low risk
Tobacco useCompleted todayNever smoked
Intimate partner violence screeningCompleted todayNegative; she feels safe
Cervical cancer screeningUp to dateCytology two years ago normal; next at three years
Chlamydia and gonorrhea screeningNot indicatedOver 24 and not at increased risk
HIV, hepatitis B and hepatitis C screeningUp to dateAll negative before treatment
Influenza vaccineCompleted todayInactivated vaccine, about five weeks before the next ocrelizumab dose
COVID-19 vaccineCompleted todayThis season's mRNA vaccine
Pneumococcal vaccineUp to datePCV20 before treatment, for an adult starting immunosuppressive therapy
Recombinant zoster vaccineUp to dateTwo doses, before and during treatment
Hepatitis B vaccineDueTwo doses given; the surface antibody check after the series is due with next month's blood tests
HPV vaccineUp to dateSeries completed in adolescence
Tetanus, diphtheria, and pertussisUp to dateTdap three years ago
Live vaccines (MMR, varicella)Not indicatedImmune to measles and varicella; live vaccines are avoided on ocrelizumab
Contraception counselingCompleted todayCondoms used consistently; IUD or implant offered for more reliable protection during treatment
Dental and vision examinationDueDental check due; eye examination normal today on fundoscopy, optometry yearly

Immunizations given today: Influenza vaccine, this season (inactivated); COVID-19 mRNA vaccine, this season's formula [S]

Guideline basis: Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Cervical Cancer: Screening (2018); Adult Immunization Schedule by Medical Condition and Other Indication (2026)

Follow-up: Ocrelizumab 600 mg next month with blood tests and hepatitis B surface antibody beforehand. Cervical screening next year. Next preventive visit in one year. Next scheduled visit 1973-10-12: six months: first 600 mg dose of ocrelizumab, no evidence of disease activity, immunoglobulins, vaccination response, pregnancy planning and her return to performing. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 15 minutes, with her consent. She named a health care agent, recorded in the confidential part of the chart and not named here. She said that she wants to be told plainly about her illness and its treatment, that she wants every treatment that can keep her playing and independent, and that if she were ever too ill to decide she would want her wishes about music and comfort respected. To be revisited at each change in her health and at least yearly. [S]